Social Media Ideas for Astellas Pharma

Astellas Becomes Host City Partner for One Young World 2027 Tokyo Summit

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has become the first Host City Partner for the One Young World 2027 Tokyo Su...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice

AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and...

<![CDATA[Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement ]]>

<![CDATA[Eli Lilly to Acquire AtaiBeckley for $2.8 Billion ]]>

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China]]>

<![CDATA[Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience]]>

<![CDATA[Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals ]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca

BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.

<![CDATA[Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly]]>

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Ent...

<![CDATA[Aptar and Aceso Therapeutics Enter Collaboration for Cystic Fibrosis Therapy ]]>

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve...

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

<![CDATA[The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan]]>